nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—PTK2B—melanoma	0.539	1	CbGaD
Leflunomide—ABCG2—Vemurafenib—melanoma	0.0864	0.307	CbGbCtD
Leflunomide—ABCG2—Dactinomycin—melanoma	0.0574	0.204	CbGbCtD
Leflunomide—CYP1A2—Carmustine—melanoma	0.0451	0.16	CbGbCtD
Leflunomide—CYP1A2—Vemurafenib—melanoma	0.0356	0.127	CbGbCtD
Leflunomide—ABCG2—Docetaxel—melanoma	0.0297	0.105	CbGbCtD
Leflunomide—CYP1A2—Dacarbazine—melanoma	0.0273	0.097	CbGbCtD
Leflunomide—Pharyngitis—Temozolomide—melanoma	0.000181	0.00194	CcSEcCtD
Leflunomide—Chills—Dactinomycin—melanoma	0.000181	0.00194	CcSEcCtD
Leflunomide—Urinary tract disorder—Temozolomide—melanoma	0.00018	0.00193	CcSEcCtD
Leflunomide—Oedema peripheral—Temozolomide—melanoma	0.000179	0.00193	CcSEcCtD
Leflunomide—Pruritus—Vemurafenib—melanoma	0.000179	0.00192	CcSEcCtD
Leflunomide—Connective tissue disorder—Temozolomide—melanoma	0.000179	0.00192	CcSEcCtD
Leflunomide—Urethral disorder—Temozolomide—melanoma	0.000178	0.00192	CcSEcCtD
Leflunomide—Alopecia—Dactinomycin—melanoma	0.000178	0.00191	CcSEcCtD
Leflunomide—Eye disorder—Carmustine—melanoma	0.000176	0.00189	CcSEcCtD
Leflunomide—Ill-defined disorder—Bleomycin—melanoma	0.000174	0.00187	CcSEcCtD
Leflunomide—Anaemia—Bleomycin—melanoma	0.000174	0.00186	CcSEcCtD
Leflunomide—Diarrhoea—Vemurafenib—melanoma	0.000173	0.00186	CcSEcCtD
Leflunomide—Migraine—Docetaxel—melanoma	0.000172	0.00185	CcSEcCtD
Leflunomide—Erythema multiforme—Temozolomide—melanoma	0.000172	0.00185	CcSEcCtD
Leflunomide—Eye disorder—Temozolomide—melanoma	0.00017	0.00183	CcSEcCtD
Leflunomide—Malaise—Bleomycin—melanoma	0.000169	0.00182	CcSEcCtD
Leflunomide—Cardiac disorder—Temozolomide—melanoma	0.000169	0.00181	CcSEcCtD
Leflunomide—Arrhythmia—Carmustine—melanoma	0.000168	0.00181	CcSEcCtD
Leflunomide—Leukopenia—Bleomycin—melanoma	0.000168	0.00181	CcSEcCtD
Leflunomide—Dizziness—Vemurafenib—melanoma	0.000167	0.0018	CcSEcCtD
Leflunomide—Alopecia—Carmustine—melanoma	0.000166	0.00179	CcSEcCtD
Leflunomide—Mental disorder—Carmustine—melanoma	0.000165	0.00177	CcSEcCtD
Leflunomide—Immune system disorder—Temozolomide—melanoma	0.000164	0.00177	CcSEcCtD
Leflunomide—Mediastinal disorder—Temozolomide—melanoma	0.000164	0.00176	CcSEcCtD
Leflunomide—Malnutrition—Carmustine—melanoma	0.000164	0.00176	CcSEcCtD
Leflunomide—Cough—Bleomycin—melanoma	0.000164	0.00176	CcSEcCtD
Leflunomide—Chills—Temozolomide—melanoma	0.000163	0.00175	CcSEcCtD
Leflunomide—Ill-defined disorder—Dactinomycin—melanoma	0.000163	0.00175	CcSEcCtD
Leflunomide—Anaemia—Dactinomycin—melanoma	0.000162	0.00174	CcSEcCtD
Leflunomide—Liver function test abnormal—Docetaxel—melanoma	0.000162	0.00173	CcSEcCtD
Leflunomide—Vomiting—Vemurafenib—melanoma	0.000161	0.00173	CcSEcCtD
Leflunomide—Alopecia—Temozolomide—melanoma	0.000161	0.00173	CcSEcCtD
Leflunomide—Dry skin—Docetaxel—melanoma	0.00016	0.00172	CcSEcCtD
Leflunomide—Chest pain—Bleomycin—melanoma	0.00016	0.00172	CcSEcCtD
Leflunomide—Myalgia—Bleomycin—melanoma	0.00016	0.00172	CcSEcCtD
Leflunomide—Rash—Vemurafenib—melanoma	0.00016	0.00171	CcSEcCtD
Leflunomide—Mental disorder—Temozolomide—melanoma	0.000159	0.00171	CcSEcCtD
Leflunomide—Dermatitis—Vemurafenib—melanoma	0.000159	0.00171	CcSEcCtD
Leflunomide—Back pain—Carmustine—melanoma	0.000159	0.0017	CcSEcCtD
Leflunomide—Headache—Vemurafenib—melanoma	0.000158	0.0017	CcSEcCtD
Leflunomide—Malnutrition—Temozolomide—melanoma	0.000158	0.0017	CcSEcCtD
Leflunomide—Breast disorder—Docetaxel—melanoma	0.000158	0.0017	CcSEcCtD
Leflunomide—Discomfort—Bleomycin—melanoma	0.000158	0.0017	CcSEcCtD
Leflunomide—Malaise—Dactinomycin—melanoma	0.000158	0.0017	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000158	0.00169	CcSEcCtD
Leflunomide—Cramp muscle—Docetaxel—melanoma	0.000158	0.00169	CcSEcCtD
Leflunomide—Leukopenia—Dactinomycin—melanoma	0.000157	0.00168	CcSEcCtD
Leflunomide—Dysgeusia—Temozolomide—melanoma	0.000155	0.00167	CcSEcCtD
Leflunomide—Vision blurred—Carmustine—melanoma	0.000155	0.00166	CcSEcCtD
Leflunomide—Anaphylactic shock—Bleomycin—melanoma	0.000153	0.00165	CcSEcCtD
Leflunomide—Back pain—Temozolomide—melanoma	0.000153	0.00165	CcSEcCtD
Leflunomide—Infection—Bleomycin—melanoma	0.000152	0.00164	CcSEcCtD
Leflunomide—Niflumic Acid—PTGS2—melanoma	0.000152	1	CrCbGaD
Leflunomide—Anaemia—Carmustine—melanoma	0.000152	0.00163	CcSEcCtD
Leflunomide—Nausea—Vemurafenib—melanoma	0.00015	0.00161	CcSEcCtD
Leflunomide—Thrombocytopenia—Bleomycin—melanoma	0.00015	0.00161	CcSEcCtD
Leflunomide—Vision blurred—Temozolomide—melanoma	0.000149	0.0016	CcSEcCtD
Leflunomide—Myalgia—Dactinomycin—melanoma	0.000149	0.0016	CcSEcCtD
Leflunomide—Discomfort—Dactinomycin—melanoma	0.000147	0.00158	CcSEcCtD
Leflunomide—Angina pectoris—Docetaxel—melanoma	0.000147	0.00158	CcSEcCtD
Leflunomide—Ill-defined disorder—Temozolomide—melanoma	0.000147	0.00158	CcSEcCtD
Leflunomide—Leukopenia—Carmustine—melanoma	0.000147	0.00158	CcSEcCtD
Leflunomide—Anaemia—Temozolomide—melanoma	0.000146	0.00157	CcSEcCtD
Leflunomide—Anorexia—Bleomycin—melanoma	0.000146	0.00157	CcSEcCtD
Leflunomide—Angioedema—Temozolomide—melanoma	0.000145	0.00155	CcSEcCtD
Leflunomide—Pancytopenia—Docetaxel—melanoma	0.000144	0.00154	CcSEcCtD
Leflunomide—Hypotension—Bleomycin—melanoma	0.000143	0.00154	CcSEcCtD
Leflunomide—Malaise—Temozolomide—melanoma	0.000143	0.00153	CcSEcCtD
Leflunomide—Vertigo—Temozolomide—melanoma	0.000142	0.00153	CcSEcCtD
Leflunomide—Infection—Dactinomycin—melanoma	0.000142	0.00153	CcSEcCtD
Leflunomide—Leukopenia—Temozolomide—melanoma	0.000142	0.00152	CcSEcCtD
Leflunomide—Hypertension—Carmustine—melanoma	0.000142	0.00152	CcSEcCtD
Leflunomide—Neutropenia—Docetaxel—melanoma	0.000141	0.00152	CcSEcCtD
Leflunomide—Palpitations—Temozolomide—melanoma	0.00014	0.0015	CcSEcCtD
Leflunomide—Thrombocytopenia—Dactinomycin—melanoma	0.00014	0.0015	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Bleomycin—melanoma	0.00014	0.0015	CcSEcCtD
Leflunomide—Chest pain—Carmustine—melanoma	0.00014	0.0015	CcSEcCtD
Leflunomide—Myalgia—Carmustine—melanoma	0.00014	0.0015	CcSEcCtD
Leflunomide—Anxiety—Carmustine—melanoma	0.000139	0.00149	CcSEcCtD
Leflunomide—Cough—Temozolomide—melanoma	0.000138	0.00148	CcSEcCtD
Leflunomide—Paraesthesia—Bleomycin—melanoma	0.000138	0.00148	CcSEcCtD
Leflunomide—Weight decreased—Docetaxel—melanoma	0.000137	0.00147	CcSEcCtD
Leflunomide—Hypertension—Temozolomide—melanoma	0.000137	0.00147	CcSEcCtD
Leflunomide—Dyspnoea—Bleomycin—melanoma	0.000137	0.00147	CcSEcCtD
Leflunomide—Anorexia—Dactinomycin—melanoma	0.000136	0.00146	CcSEcCtD
Leflunomide—Pneumonia—Docetaxel—melanoma	0.000136	0.00146	CcSEcCtD
Leflunomide—Arthralgia—Temozolomide—melanoma	0.000135	0.00145	CcSEcCtD
Leflunomide—Myalgia—Temozolomide—melanoma	0.000135	0.00145	CcSEcCtD
Leflunomide—Infestation—Docetaxel—melanoma	0.000135	0.00145	CcSEcCtD
Leflunomide—Infestation NOS—Docetaxel—melanoma	0.000135	0.00145	CcSEcCtD
Leflunomide—Anxiety—Temozolomide—melanoma	0.000134	0.00144	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000134	0.00144	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000134	0.00144	CcSEcCtD
Leflunomide—Discomfort—Temozolomide—melanoma	0.000133	0.00143	CcSEcCtD
Leflunomide—Decreased appetite—Bleomycin—melanoma	0.000133	0.00143	CcSEcCtD
Leflunomide—Infection—Carmustine—melanoma	0.000133	0.00143	CcSEcCtD
Leflunomide—Renal failure—Docetaxel—melanoma	0.000133	0.00142	CcSEcCtD
Leflunomide—Neuropathy peripheral—Docetaxel—melanoma	0.000132	0.00142	CcSEcCtD
Leflunomide—Dry mouth—Temozolomide—melanoma	0.000132	0.00142	CcSEcCtD
Leflunomide—Stomatitis—Docetaxel—melanoma	0.000131	0.00141	CcSEcCtD
Leflunomide—Jaundice—Docetaxel—melanoma	0.000131	0.00141	CcSEcCtD
Leflunomide—Pain—Bleomycin—melanoma	0.000131	0.00141	CcSEcCtD
Leflunomide—Conjunctivitis—Docetaxel—melanoma	0.000131	0.00141	CcSEcCtD
Leflunomide—Thrombocytopenia—Carmustine—melanoma	0.000131	0.00141	CcSEcCtD
Leflunomide—Tachycardia—Carmustine—melanoma	0.000131	0.0014	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00013	0.0014	CcSEcCtD
Leflunomide—Anaphylactic shock—Temozolomide—melanoma	0.000129	0.00139	CcSEcCtD
Leflunomide—Infection—Temozolomide—melanoma	0.000128	0.00138	CcSEcCtD
Leflunomide—Anorexia—Carmustine—melanoma	0.000128	0.00137	CcSEcCtD
Leflunomide—Hepatobiliary disease—Docetaxel—melanoma	0.000128	0.00137	CcSEcCtD
Leflunomide—Epistaxis—Docetaxel—melanoma	0.000127	0.00137	CcSEcCtD
Leflunomide—Nervous system disorder—Temozolomide—melanoma	0.000127	0.00136	CcSEcCtD
Leflunomide—Thrombocytopenia—Temozolomide—melanoma	0.000127	0.00136	CcSEcCtD
Leflunomide—Feeling abnormal—Bleomycin—melanoma	0.000126	0.00136	CcSEcCtD
Leflunomide—Agranulocytosis—Docetaxel—melanoma	0.000126	0.00135	CcSEcCtD
Leflunomide—Skin disorder—Temozolomide—melanoma	0.000126	0.00135	CcSEcCtD
Leflunomide—Hypotension—Carmustine—melanoma	0.000125	0.00134	CcSEcCtD
Leflunomide—Hyperhidrosis—Temozolomide—melanoma	0.000125	0.00134	CcSEcCtD
Leflunomide—Decreased appetite—Dactinomycin—melanoma	0.000124	0.00133	CcSEcCtD
Leflunomide—Fatigue—Dactinomycin—melanoma	0.000123	0.00132	CcSEcCtD
Leflunomide—Anorexia—Temozolomide—melanoma	0.000123	0.00132	CcSEcCtD
Leflunomide—Pain—Dactinomycin—melanoma	0.000122	0.00131	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Carmustine—melanoma	0.000122	0.00131	CcSEcCtD
Leflunomide—Urticaria—Bleomycin—melanoma	0.000122	0.00131	CcSEcCtD
Leflunomide—Haemoglobin—Docetaxel—melanoma	0.000122	0.00131	CcSEcCtD
Leflunomide—Rhinitis—Docetaxel—melanoma	0.000121	0.0013	CcSEcCtD
Leflunomide—Body temperature increased—Bleomycin—melanoma	0.000121	0.0013	CcSEcCtD
Leflunomide—Hepatitis—Docetaxel—melanoma	0.000121	0.0013	CcSEcCtD
Leflunomide—Haemorrhage—Docetaxel—melanoma	0.000121	0.0013	CcSEcCtD
Leflunomide—Insomnia—Carmustine—melanoma	0.000121	0.0013	CcSEcCtD
Leflunomide—Paraesthesia—Carmustine—melanoma	0.00012	0.00129	CcSEcCtD
Leflunomide—Pharyngitis—Docetaxel—melanoma	0.00012	0.00129	CcSEcCtD
Leflunomide—Urinary tract disorder—Docetaxel—melanoma	0.00012	0.00128	CcSEcCtD
Leflunomide—Dyspnoea—Carmustine—melanoma	0.000119	0.00128	CcSEcCtD
Leflunomide—Oedema peripheral—Docetaxel—melanoma	0.000119	0.00128	CcSEcCtD
Leflunomide—Connective tissue disorder—Docetaxel—melanoma	0.000119	0.00128	CcSEcCtD
Leflunomide—Urethral disorder—Docetaxel—melanoma	0.000119	0.00127	CcSEcCtD
Leflunomide—Feeling abnormal—Dactinomycin—melanoma	0.000118	0.00127	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Temozolomide—melanoma	0.000118	0.00127	CcSEcCtD
Leflunomide—Insomnia—Temozolomide—melanoma	0.000117	0.00126	CcSEcCtD
Leflunomide—Gastrointestinal pain—Dactinomycin—melanoma	0.000117	0.00126	CcSEcCtD
Leflunomide—Decreased appetite—Carmustine—melanoma	0.000116	0.00125	CcSEcCtD
Leflunomide—Paraesthesia—Temozolomide—melanoma	0.000116	0.00125	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Carmustine—melanoma	0.000116	0.00124	CcSEcCtD
Leflunomide—Dyspnoea—Temozolomide—melanoma	0.000115	0.00124	CcSEcCtD
Leflunomide—Erythema multiforme—Docetaxel—melanoma	0.000114	0.00123	CcSEcCtD
Leflunomide—Pain—Carmustine—melanoma	0.000114	0.00123	CcSEcCtD
Leflunomide—Constipation—Carmustine—melanoma	0.000114	0.00123	CcSEcCtD
Leflunomide—Dyspepsia—Temozolomide—melanoma	0.000114	0.00122	CcSEcCtD
Leflunomide—Eye disorder—Docetaxel—melanoma	0.000113	0.00121	CcSEcCtD
Leflunomide—Abdominal pain—Dactinomycin—melanoma	0.000113	0.00121	CcSEcCtD
Leflunomide—Body temperature increased—Dactinomycin—melanoma	0.000113	0.00121	CcSEcCtD
Leflunomide—Hypersensitivity—Bleomycin—melanoma	0.000113	0.00121	CcSEcCtD
Leflunomide—Decreased appetite—Temozolomide—melanoma	0.000112	0.00121	CcSEcCtD
Leflunomide—Cardiac disorder—Docetaxel—melanoma	0.000112	0.00121	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Temozolomide—melanoma	0.000112	0.0012	CcSEcCtD
Leflunomide—Fatigue—Temozolomide—melanoma	0.000111	0.0012	CcSEcCtD
Leflunomide—Pain—Temozolomide—melanoma	0.000111	0.00119	CcSEcCtD
Leflunomide—Constipation—Temozolomide—melanoma	0.000111	0.00119	CcSEcCtD
Leflunomide—Feeling abnormal—Carmustine—melanoma	0.00011	0.00118	CcSEcCtD
Leflunomide—Asthenia—Bleomycin—melanoma	0.00011	0.00118	CcSEcCtD
Leflunomide—Gastrointestinal pain—Carmustine—melanoma	0.000109	0.00118	CcSEcCtD
Leflunomide—Immune system disorder—Docetaxel—melanoma	0.000109	0.00117	CcSEcCtD
Leflunomide—Mediastinal disorder—Docetaxel—melanoma	0.000109	0.00117	CcSEcCtD
Leflunomide—Chills—Docetaxel—melanoma	0.000109	0.00117	CcSEcCtD
Leflunomide—Pruritus—Bleomycin—melanoma	0.000108	0.00116	CcSEcCtD
Leflunomide—Arrhythmia—Docetaxel—melanoma	0.000108	0.00116	CcSEcCtD
Leflunomide—Alopecia—Docetaxel—melanoma	0.000107	0.00115	CcSEcCtD
Leflunomide—Feeling abnormal—Temozolomide—melanoma	0.000107	0.00114	CcSEcCtD
Leflunomide—Mental disorder—Docetaxel—melanoma	0.000106	0.00114	CcSEcCtD
Leflunomide—Abdominal pain—Carmustine—melanoma	0.000106	0.00114	CcSEcCtD
Leflunomide—Body temperature increased—Carmustine—melanoma	0.000106	0.00114	CcSEcCtD
Leflunomide—Gastrointestinal pain—Temozolomide—melanoma	0.000106	0.00114	CcSEcCtD
Leflunomide—Malnutrition—Docetaxel—melanoma	0.000105	0.00113	CcSEcCtD
Leflunomide—Hypersensitivity—Dactinomycin—melanoma	0.000105	0.00113	CcSEcCtD
Leflunomide—Dysgeusia—Docetaxel—melanoma	0.000103	0.00111	CcSEcCtD
Leflunomide—Urticaria—Temozolomide—melanoma	0.000103	0.0011	CcSEcCtD
Leflunomide—Asthenia—Dactinomycin—melanoma	0.000103	0.0011	CcSEcCtD
Leflunomide—Abdominal pain—Temozolomide—melanoma	0.000102	0.0011	CcSEcCtD
Leflunomide—Body temperature increased—Temozolomide—melanoma	0.000102	0.0011	CcSEcCtD
Leflunomide—Back pain—Docetaxel—melanoma	0.000102	0.00109	CcSEcCtD
Leflunomide—Muscle spasms—Docetaxel—melanoma	0.000101	0.00109	CcSEcCtD
Leflunomide—Hypersensitivity—Carmustine—melanoma	9.86e-05	0.00106	CcSEcCtD
Leflunomide—Diarrhoea—Dactinomycin—melanoma	9.78e-05	0.00105	CcSEcCtD
Leflunomide—Vomiting—Bleomycin—melanoma	9.75e-05	0.00105	CcSEcCtD
Leflunomide—Anaemia—Docetaxel—melanoma	9.74e-05	0.00105	CcSEcCtD
Leflunomide—Rash—Bleomycin—melanoma	9.66e-05	0.00104	CcSEcCtD
Leflunomide—Dermatitis—Bleomycin—melanoma	9.66e-05	0.00104	CcSEcCtD
Leflunomide—Asthenia—Carmustine—melanoma	9.6e-05	0.00103	CcSEcCtD
Leflunomide—Hypersensitivity—Temozolomide—melanoma	9.53e-05	0.00102	CcSEcCtD
Leflunomide—Leukopenia—Docetaxel—melanoma	9.43e-05	0.00101	CcSEcCtD
Leflunomide—Palpitations—Docetaxel—melanoma	9.31e-05	0.001	CcSEcCtD
Leflunomide—Asthenia—Temozolomide—melanoma	9.28e-05	0.000996	CcSEcCtD
Leflunomide—Cough—Docetaxel—melanoma	9.19e-05	0.000988	CcSEcCtD
Leflunomide—Diarrhoea—Carmustine—melanoma	9.15e-05	0.000983	CcSEcCtD
Leflunomide—Pruritus—Temozolomide—melanoma	9.15e-05	0.000983	CcSEcCtD
Leflunomide—Nausea—Bleomycin—melanoma	9.1e-05	0.000978	CcSEcCtD
Leflunomide—Hypertension—Docetaxel—melanoma	9.1e-05	0.000977	CcSEcCtD
Leflunomide—Vomiting—Dactinomycin—melanoma	9.09e-05	0.000976	CcSEcCtD
Leflunomide—Rash—Dactinomycin—melanoma	9.01e-05	0.000968	CcSEcCtD
Leflunomide—Myalgia—Docetaxel—melanoma	8.97e-05	0.000963	CcSEcCtD
Leflunomide—Arthralgia—Docetaxel—melanoma	8.97e-05	0.000963	CcSEcCtD
Leflunomide—Chest pain—Docetaxel—melanoma	8.97e-05	0.000963	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	8.91e-05	0.000957	CcSEcCtD
Leflunomide—Dizziness—Carmustine—melanoma	8.85e-05	0.00095	CcSEcCtD
Leflunomide—Diarrhoea—Temozolomide—melanoma	8.85e-05	0.00095	CcSEcCtD
Leflunomide—Dry mouth—Docetaxel—melanoma	8.77e-05	0.000942	CcSEcCtD
Leflunomide—Anaphylactic shock—Docetaxel—melanoma	8.6e-05	0.000924	CcSEcCtD
Leflunomide—Dizziness—Temozolomide—melanoma	8.55e-05	0.000918	CcSEcCtD
Leflunomide—Infection—Docetaxel—melanoma	8.54e-05	0.000918	CcSEcCtD
Leflunomide—Vomiting—Carmustine—melanoma	8.51e-05	0.000914	CcSEcCtD
Leflunomide—Nausea—Dactinomycin—melanoma	8.49e-05	0.000912	CcSEcCtD
Leflunomide—Rash—Carmustine—melanoma	8.44e-05	0.000906	CcSEcCtD
Leflunomide—Nervous system disorder—Docetaxel—melanoma	8.43e-05	0.000906	CcSEcCtD
Leflunomide—Dermatitis—Carmustine—melanoma	8.43e-05	0.000905	CcSEcCtD
Leflunomide—Thrombocytopenia—Docetaxel—melanoma	8.42e-05	0.000904	CcSEcCtD
Leflunomide—Tachycardia—Docetaxel—melanoma	8.39e-05	0.000901	CcSEcCtD
Leflunomide—Headache—Carmustine—melanoma	8.38e-05	0.0009	CcSEcCtD
Leflunomide—Skin disorder—Docetaxel—melanoma	8.35e-05	0.000897	CcSEcCtD
Leflunomide—Vomiting—Temozolomide—melanoma	8.22e-05	0.000883	CcSEcCtD
Leflunomide—Anorexia—Docetaxel—melanoma	8.2e-05	0.00088	CcSEcCtD
Leflunomide—Rash—Temozolomide—melanoma	8.15e-05	0.000876	CcSEcCtD
Leflunomide—Dermatitis—Temozolomide—melanoma	8.14e-05	0.000875	CcSEcCtD
Leflunomide—Headache—Temozolomide—melanoma	8.1e-05	0.00087	CcSEcCtD
Leflunomide—Hypotension—Docetaxel—melanoma	8.03e-05	0.000863	CcSEcCtD
Leflunomide—Nausea—Carmustine—melanoma	7.95e-05	0.000854	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Docetaxel—melanoma	7.83e-05	0.000841	CcSEcCtD
Leflunomide—Insomnia—Docetaxel—melanoma	7.78e-05	0.000835	CcSEcCtD
Leflunomide—Paraesthesia—Docetaxel—melanoma	7.72e-05	0.000829	CcSEcCtD
Leflunomide—Nausea—Temozolomide—melanoma	7.68e-05	0.000825	CcSEcCtD
Leflunomide—Dyspnoea—Docetaxel—melanoma	7.67e-05	0.000823	CcSEcCtD
Leflunomide—Dyspepsia—Docetaxel—melanoma	7.57e-05	0.000813	CcSEcCtD
Leflunomide—Decreased appetite—Docetaxel—melanoma	7.47e-05	0.000803	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Docetaxel—melanoma	7.42e-05	0.000797	CcSEcCtD
Leflunomide—Fatigue—Docetaxel—melanoma	7.41e-05	0.000796	CcSEcCtD
Leflunomide—Pain—Docetaxel—melanoma	7.35e-05	0.00079	CcSEcCtD
Leflunomide—Constipation—Docetaxel—melanoma	7.35e-05	0.00079	CcSEcCtD
Leflunomide—Feeling abnormal—Docetaxel—melanoma	7.09e-05	0.000761	CcSEcCtD
Leflunomide—Gastrointestinal pain—Docetaxel—melanoma	7.03e-05	0.000755	CcSEcCtD
Leflunomide—Abdominal pain—Docetaxel—melanoma	6.8e-05	0.00073	CcSEcCtD
Leflunomide—Body temperature increased—Docetaxel—melanoma	6.8e-05	0.00073	CcSEcCtD
Leflunomide—Hypersensitivity—Docetaxel—melanoma	6.34e-05	0.00068	CcSEcCtD
Leflunomide—Asthenia—Docetaxel—melanoma	6.17e-05	0.000663	CcSEcCtD
Leflunomide—Pruritus—Docetaxel—melanoma	6.08e-05	0.000653	CcSEcCtD
Leflunomide—Diarrhoea—Docetaxel—melanoma	5.88e-05	0.000632	CcSEcCtD
Leflunomide—Dizziness—Docetaxel—melanoma	5.69e-05	0.000611	CcSEcCtD
Leflunomide—Vomiting—Docetaxel—melanoma	5.47e-05	0.000587	CcSEcCtD
Leflunomide—Rash—Docetaxel—melanoma	5.42e-05	0.000582	CcSEcCtD
Leflunomide—Dermatitis—Docetaxel—melanoma	5.42e-05	0.000582	CcSEcCtD
Leflunomide—Headache—Docetaxel—melanoma	5.39e-05	0.000579	CcSEcCtD
Leflunomide—Nausea—Docetaxel—melanoma	5.11e-05	0.000549	CcSEcCtD
Leflunomide—PTK2B—Immune System—HGF—melanoma	1.98e-05	0.000229	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—F2R—melanoma	1.96e-05	0.000227	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—melanoma	1.96e-05	0.000227	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—melanoma	1.96e-05	0.000227	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD8A—melanoma	1.96e-05	0.000226	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CSF2—melanoma	1.96e-05	0.000226	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FGF1—melanoma	1.96e-05	0.000226	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—melanoma	1.95e-05	0.000225	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—melanoma	1.94e-05	0.000225	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EDNRB—melanoma	1.9e-05	0.00022	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PDGFRA—melanoma	1.9e-05	0.000219	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-B—melanoma	1.88e-05	0.000217	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PRKCA—melanoma	1.88e-05	0.000217	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL6—melanoma	1.86e-05	0.000215	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GPAM—melanoma	1.86e-05	0.000215	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAP2K2—melanoma	1.83e-05	0.000212	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PHGDH—melanoma	1.82e-05	0.00021	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—LUM—melanoma	1.82e-05	0.00021	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GAB2—melanoma	1.8e-05	0.000207	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GNA11—melanoma	1.8e-05	0.000207	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FLT1—melanoma	1.79e-05	0.000206	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HPSE—melanoma	1.79e-05	0.000206	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CUBN—melanoma	1.75e-05	0.000203	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ACER3—melanoma	1.75e-05	0.000202	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-A—melanoma	1.74e-05	0.000201	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RAC1—melanoma	1.74e-05	0.000201	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CUBN—melanoma	1.7e-05	0.000196	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SDHD—melanoma	1.69e-05	0.000196	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—BSG—melanoma	1.69e-05	0.000196	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CSPG4—melanoma	1.69e-05	0.000196	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HDAC2—melanoma	1.69e-05	0.000195	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCR4—melanoma	1.69e-05	0.000195	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FOXO4—melanoma	1.69e-05	0.000195	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GNAQ—melanoma	1.67e-05	0.000193	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—melanoma	1.66e-05	0.000191	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GPAM—melanoma	1.64e-05	0.000189	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—UGT2B10—melanoma	1.6e-05	0.000185	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR4—melanoma	1.6e-05	0.000184	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-DRB1—melanoma	1.59e-05	0.000184	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GPAM—melanoma	1.59e-05	0.000184	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	1.58e-05	0.000183	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SYK—melanoma	1.57e-05	0.000181	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ABCB1—melanoma	1.56e-05	0.000181	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NGFR—melanoma	1.54e-05	0.000178	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ITGAV—melanoma	1.54e-05	0.000178	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT3—melanoma	1.54e-05	0.000178	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ICAM1—melanoma	1.53e-05	0.000177	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CA—melanoma	1.53e-05	0.000176	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ACER3—melanoma	1.5e-05	0.000173	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HS3ST5—melanoma	1.49e-05	0.000172	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD80—melanoma	1.47e-05	0.00017	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KIT—melanoma	1.47e-05	0.00017	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGF—melanoma	1.45e-05	0.000168	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SOCS1—melanoma	1.43e-05	0.000165	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—S100B—melanoma	1.42e-05	0.000164	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PLA2G6—melanoma	1.4e-05	0.000161	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—UGT2B10—melanoma	1.37e-05	0.000158	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CASP8—melanoma	1.37e-05	0.000158	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB4—melanoma	1.36e-05	0.000157	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDH1—melanoma	1.35e-05	0.000156	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	1.35e-05	0.000156	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN2B—melanoma	1.35e-05	0.000156	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CD86—melanoma	1.31e-05	0.000151	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAP2K1—melanoma	1.3e-05	0.00015	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EDN1—melanoma	1.29e-05	0.00015	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CD—melanoma	1.29e-05	0.000149	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HS3ST5—melanoma	1.27e-05	0.000147	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CSF2—melanoma	1.27e-05	0.000146	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FGF1—melanoma	1.27e-05	0.000146	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—VCAN—melanoma	1.25e-05	0.000145	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—melanoma	1.25e-05	0.000144	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—E2F1—melanoma	1.24e-05	0.000143	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FGF2—melanoma	1.24e-05	0.000143	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PDGFRA—melanoma	1.23e-05	0.000142	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ITGB3—melanoma	1.21e-05	0.00014	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PRKCA—melanoma	1.21e-05	0.00014	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	1.2e-05	0.000138	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SPP1—melanoma	1.19e-05	0.000137	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAP2K2—melanoma	1.19e-05	0.000137	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—BCL2—melanoma	1.17e-05	0.000136	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNG—melanoma	1.16e-05	0.000134	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MDM2—melanoma	1.16e-05	0.000134	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ERBB2—melanoma	1.14e-05	0.000132	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PLCB4—melanoma	1.13e-05	0.00013	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TERT—melanoma	1.13e-05	0.00013	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CB—melanoma	1.13e-05	0.00013	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RAC1—melanoma	1.12e-05	0.00013	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD4—melanoma	1.12e-05	0.00013	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—FASN—melanoma	1.11e-05	0.000128	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HIF1A—melanoma	1.08e-05	0.000125	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIP4K2A—melanoma	1.06e-05	0.000123	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC6A11—melanoma	1.06e-05	0.000123	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP17A1—melanoma	1.06e-05	0.000122	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1B—melanoma	1.06e-05	0.000122	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2—melanoma	1.03e-05	0.000119	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MTAP—melanoma	1.03e-05	0.000119	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KDR—melanoma	1.03e-05	0.000119	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	1.02e-05	0.000118	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	1.01e-05	0.000117	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GNA11—melanoma	9.99e-06	0.000115	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTNNB1—melanoma	9.99e-06	0.000115	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FN1—melanoma	9.93e-06	0.000115	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ALB—melanoma	9.79e-06	0.000113	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—FASN—melanoma	9.77e-06	0.000113	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1A—melanoma	9.75e-06	0.000113	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTEN—melanoma	9.73e-06	0.000112	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH1—melanoma	9.72e-06	0.000112	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NFKB1—melanoma	9.69e-06	0.000112	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PLCB4—melanoma	9.65e-06	0.000111	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC5A5—melanoma	9.61e-06	0.000111	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CD80—melanoma	9.52e-06	0.00011	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CG—melanoma	9.5e-06	0.00011	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KIT—melanoma	9.5e-06	0.00011	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APC—melanoma	9.5e-06	0.00011	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—FASN—melanoma	9.47e-06	0.000109	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGF—melanoma	9.39e-06	0.000108	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CD44—melanoma	9.28e-06	0.000107	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GNAQ—melanoma	9.28e-06	0.000107	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PHGDH—melanoma	9.21e-06	0.000106	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LUM—melanoma	9.21e-06	0.000106	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC6A11—melanoma	9.07e-06	0.000105	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIP4K2A—melanoma	9.07e-06	0.000105	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HPSE—melanoma	9.03e-06	0.000104	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BRAF—melanoma	8.93e-06	0.000103	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP1B1—melanoma	8.9e-06	0.000103	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CUBN—melanoma	8.86e-06	0.000102	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MTAP—melanoma	8.83e-06	0.000102	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT3—melanoma	8.7e-06	0.000101	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF1—melanoma	8.7e-06	0.0001	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NRAS—melanoma	8.68e-06	0.0001	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	8.63e-06	9.96e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SDHD—melanoma	8.56e-06	9.88e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—BSG—melanoma	8.56e-06	9.88e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CSPG4—melanoma	8.56e-06	9.88e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAP2K1—melanoma	8.41e-06	9.71e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CD—melanoma	8.35e-06	9.65e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK3—melanoma	8.32e-06	9.6e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GPAM—melanoma	8.29e-06	9.57e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FGF2—melanoma	8e-06	9.24e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK1—melanoma	7.91e-06	9.14e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—melanoma	7.91e-06	9.13e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PHGDH—melanoma	7.87e-06	9.08e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LUM—melanoma	7.87e-06	9.08e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HPSE—melanoma	7.71e-06	8.91e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CUBN—melanoma	7.57e-06	8.74e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MDM2—melanoma	7.48e-06	8.64e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—melanoma	7.47e-06	8.63e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB2—melanoma	7.38e-06	8.52e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ABCB1—melanoma	7.33e-06	8.46e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SDHD—melanoma	7.31e-06	8.44e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CSPG4—melanoma	7.31e-06	8.44e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—BSG—melanoma	7.31e-06	8.44e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CB—melanoma	7.28e-06	8.41e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GPAM—melanoma	7.08e-06	8.18e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PLA2G6—melanoma	7.05e-06	8.14e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL8—melanoma	7e-06	8.08e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CA—melanoma	6.87e-06	7.93e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1B—melanoma	6.83e-06	7.89e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PRKCA—melanoma	6.75e-06	7.79e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP3—melanoma	6.7e-06	7.73e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ERCC2—melanoma	6.69e-06	7.72e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2—melanoma	6.69e-06	7.72e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—melanoma	6.52e-06	7.53e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CTNNB1—melanoma	6.46e-06	7.45e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—melanoma	6.35e-06	7.33e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—VCAN—melanoma	6.33e-06	7.31e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—melanoma	6.33e-06	7.31e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1A—melanoma	6.31e-06	7.28e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTEN—melanoma	6.29e-06	7.27e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NFKB1—melanoma	6.26e-06	7.23e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6—melanoma	6.08e-06	7.02e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PLA2G6—melanoma	6.02e-06	6.95e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	5.99e-06	6.92e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	5.78e-06	6.68e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—melanoma	5.68e-06	6.56e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT3—melanoma	5.63e-06	6.5e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NRAS—melanoma	5.61e-06	6.48e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—melanoma	5.61e-06	6.48e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—VCAN—melanoma	5.41e-06	6.25e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK3—melanoma	5.38e-06	6.21e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP17A1—melanoma	5.34e-06	6.17e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CG—melanoma	5.28e-06	6.1e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	5.27e-06	6.08e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—melanoma	5.23e-06	6.04e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	5.2e-06	6e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	5.12e-06	5.91e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK1—melanoma	5.12e-06	5.91e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—melanoma	5.11e-06	5.91e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARG—melanoma	5.1e-06	5.89e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GNA11—melanoma	5.04e-06	5.82e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	4.94e-06	5.71e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—FASN—melanoma	4.94e-06	5.7e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC5A5—melanoma	4.86e-06	5.61e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—melanoma	4.83e-06	5.58e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GNAQ—melanoma	4.69e-06	5.41e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CD44—melanoma	4.69e-06	5.41e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CD—melanoma	4.64e-06	5.36e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	4.59e-06	5.3e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALB—melanoma	4.59e-06	5.29e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP17A1—melanoma	4.56e-06	5.27e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	4.55e-06	5.25e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.5e-06	5.2e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP1B1—melanoma	4.5e-06	5.19e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	4.44e-06	5.13e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CA—melanoma	4.44e-06	5.13e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GNA11—melanoma	4.31e-06	4.98e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—melanoma	4.29e-06	4.96e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—FASN—melanoma	4.22e-06	4.87e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC5A5—melanoma	4.15e-06	4.79e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—melanoma	4.11e-06	4.74e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CB—melanoma	4.05e-06	4.67e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—melanoma	4.01e-06	4.63e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GNAQ—melanoma	4.01e-06	4.63e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CD44—melanoma	4.01e-06	4.63e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.97e-06	4.58e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6—melanoma	3.93e-06	4.54e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	3.92e-06	4.53e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	3.89e-06	4.49e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP1B1—melanoma	3.84e-06	4.44e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCB1—melanoma	3.7e-06	4.27e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—melanoma	3.63e-06	4.19e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTEN—melanoma	3.5e-06	4.04e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PRKCA—melanoma	3.41e-06	3.93e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.39e-06	3.91e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ERCC2—melanoma	3.38e-06	3.9e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCB1—melanoma	3.16e-06	3.65e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PRKCA—melanoma	2.91e-06	3.36e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ERCC2—melanoma	2.89e-06	3.33e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.8e-06	3.23e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CG—melanoma	2.67e-06	3.08e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARG—melanoma	2.58e-06	2.97e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CA—melanoma	2.47e-06	2.85e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.39e-06	2.76e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CD—melanoma	2.35e-06	2.71e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALB—melanoma	2.32e-06	2.67e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CG—melanoma	2.28e-06	2.63e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARG—melanoma	2.2e-06	2.54e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CB—melanoma	2.04e-06	2.36e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—melanoma	2.03e-06	2.34e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—melanoma	2.02e-06	2.33e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CD—melanoma	2e-06	2.31e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALB—melanoma	1.98e-06	2.29e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTEN—melanoma	1.77e-06	2.04e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CB—melanoma	1.75e-06	2.02e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—melanoma	1.73e-06	2e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTEN—melanoma	1.51e-06	1.74e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CA—melanoma	1.25e-06	1.44e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CA—melanoma	1.07e-06	1.23e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—melanoma	1.02e-06	1.18e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—melanoma	8.7e-07	1e-05	CbGpPWpGaD
